Showing results (21-30 of 33) with videos related to
Sort By:
Pageof 4
Breast Cancer Research and Treatment|August 15, 2024
Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018Erin J Aiello Bowles, Cody Ramin, Jacqueline B Vo, et al.Breast Cancer Research and Treatment|March 11, 2022
Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016Erin J Aiello Bowles, Cody Ramin, Diana S M Buist, et al.Cancer Causes & Control : CCC|May 18, 2022
The influence of treatment on hormone receptor subgroups and breast cancer-specific mortality within US integrated healthcare systemsCody Ramin, Gretchen L Gierach, Mustapha Abubakar, et al.Breast Cancer Research : BCR|May 3, 2023
Risk of second primary cancer among women in the Kaiser Permanente Breast Cancer Survivors CohortCody Ramin, Lene H S Veiga, Jacqueline B Vo, et al.Cardio-Oncology (London, England)|July 3, 2025
Dynamic cardiac changes in low cardiovascular risk patients with triple negative breast cancer treated with chemo-immunotherapyJean Philippe Nesseler, Katrina D Silos, Olivia Peony, et al.The Lancet. Oncology|October 14, 2022
Treatment-related thoracic soft tissue sarcomas in US breast cancer survivors: a retrospective cohort studyLene H S Veiga, Jacqueline B Vo, Rochelle E Curtis, et al.Journal of the National Cancer Institute|May 8, 2024
Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in US breast cancer survivorsJacqueline B Vo, Cody Ramin, Lene H S Veiga, et al.NPJ Breast Cancer|March 16, 2023
Short-term changes in ultrasound tomography measures of breast density and treatment-associated endocrine symptoms after tamoxifen therapyCody Ramin, Ruth M Pfeiffer, Sharon Fan, et al.British Journal of Cancer|November 14, 2025
Contralateral breast cancer after radiotherapy and hormone therapy in two cohorts of US breast cancer survivorsLene H S Veiga, Gretchen L Gierach, Susan A Smith, et al.Breast Cancer Research and Treatment|December 19, 2018
The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapiesBerry Button, Sarah Croessmann, David Chu, et al.Pageof 4